Breast Cancer
Conditions
Interventions
Different doses:1.Aromatase inhibitors+CDK4/6 inhibitors
2.18F-CDKi
3.18F-FES
Optimal dose:1.Aromatase inhibitors+CDK4/6 inhibitors
Sponsors
Xiang'an Hospital of Xiamen University
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Postmenopausal women; 2.Stage?-?B, ER and/or PR positive and HER2 negative breast cancer confirmed by histopathology with tumor size > 2.0 cm (ultrasound); 3. Karl Fischer score = 60 or WHO physical status score 0-2; 4. No distant metastasis; 5. No history of endocrine therapy; 6. No contraindication of radiotherapy, chemotherapy and surgery; 7. No serious basic disease; 8. Sign the informed consent voluntarily; 9. Able to comply with the agreement.
Exclusion criteria
Exclusion criteria: 1.History of other malignant tumors; 2.Other serious diseases: congenital malformation, acute inflammation, cachexia, myocardial infarction and stroke within 6 months, severe liver and kidney dysfunction,etc; 3.Pregnant or lactating women (for women with complete reproductive organs and less than two years after menopause,the certificate of negative pregnancy test must be provided); 4. Have received endocrine therapy, radiotherapy, chemotherapy or surgery before treatment; 5. Participants in another clinical trial.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Correlation between SUVmax and treatment response; | — |
Primary
| Measure | Time frame |
|---|---|
| SUVmax;Incidence of adverse reactions; | — |
Countries
China
Contacts
Public ContactGuojun Zhang
Xiang'an Hospital of Xiamen University
Outcome results
None listed